| Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now |
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-05-14 14:56:09 |
Czytaj oryginał (ang.) |
| Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-13 14:45:51 |
Czytaj oryginał (ang.) |
| Earnings Estimates Rising for Rigel (RIGL): Will It Gain? |
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-05-09 17:20:40 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet |
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-08 15:02:07 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum |
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets. |
seekingalpha.com |
2025-05-07 22:16:40 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript |
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B. |
seekingalpha.com |
2025-05-07 03:13:47 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates |
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2025-05-06 22:30:38 |
Czytaj oryginał (ang.) |
| Rigel Reports First Quarter 2025 Financial Results and Provides Business Update |
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA 2025 Outlook: Total revenue of approximately $200 to $210 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. |
prnewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update |
SOUTH SAN FRANCISCO, Calif. , April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. |
prnewswire.com |
2025-04-29 12:05:00 |
Czytaj oryginał (ang.) |
| Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? |
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-17 17:00:37 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks to Buy as the Sector Faces Government Heat |
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies. |
zacks.com |
2025-04-17 13:25:38 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability |
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability |
seekingalpha.com |
2025-04-04 19:31:25 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif. , April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). |
prnewswire.com |
2025-04-04 12:05:00 |
Czytaj oryginał (ang.) |
| Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation |
SOUTH SAN FRANCISCO, Calif. , March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd. |
prnewswire.com |
2025-03-27 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel Appoints Mark W. Frohlich, M.D. |
SOUTH SAN FRANCISCO, Calif. , March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. |
prnewswire.com |
2025-03-10 10:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade |
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-03-05 12:56:15 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript |
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citi Kalpit Patel - B. |
seekingalpha.com |
2025-03-05 01:29:05 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates |
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago. |
zacks.com |
2025-03-04 20:15:23 |
Czytaj oryginał (ang.) |
| Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 million R289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA 2025 Outlook: Total revenue of approximately $200 to $210 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. |
prnewswire.com |
2025-03-04 18:01:00 |
Czytaj oryginał (ang.) |
| Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings? |
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio. |
zacks.com |
2025-02-25 16:45:30 |
Czytaj oryginał (ang.) |
| Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update |
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. |
prnewswire.com |
2025-02-25 10:05:00 |
Czytaj oryginał (ang.) |
| RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell? |
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth. |
zacks.com |
2025-02-24 13:10:28 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks to Buy as the Sector Stages a Comeback |
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies. |
zacks.com |
2025-02-24 11:15:30 |
Czytaj oryginał (ang.) |
| Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-03 12:55:44 |
Czytaj oryginał (ang.) |
| Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease |
First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients with sickle cell disease (SCD). |
prnewswire.com |
2025-01-22 10:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-17 12:56:13 |
Czytaj oryginał (ang.) |
| Best Momentum Stock to Buy for January 17th |
WFC, FHN and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2025. |
zacks.com |
2025-01-17 10:51:10 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 17th |
RIGL, PFIS, PBPB, ICL and KMX have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2025. |
zacks.com |
2025-01-17 09:26:09 |
Czytaj oryginał (ang.) |
| Rigel (RIGL) Upgraded to Buy: Here's Why |
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-15 15:00:41 |
Czytaj oryginał (ang.) |
| Rigel Provides Business Update and 2025 Outlook |
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDS Rigel anticipates 2025 total revenue of approximately $200 to $210 million SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025. |
prnewswire.com |
2025-01-13 10:05:00 |
Czytaj oryginał (ang.) |
| Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks |
We have picked five small-cap stocks that have strong growth potential for 2025. These are: TZOO, EVER, LIND, RIGL, GHM. |
zacks.com |
2025-01-09 12:20:30 |
Czytaj oryginał (ang.) |
| Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS |
SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). |
prnewswire.com |
2025-01-09 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. |
prnewswire.com |
2025-01-08 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). |
prnewswire.com |
2025-01-03 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents |
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three approved drugs and promising candidates like R289 and ocadusertib, with notable advancements in clinical trials and Fast Track designation. Financially, RIGL has turned profitable with a $12.4 million net income in the latest quarter, but high debt and potential cash flow challenges loom. |
seekingalpha.com |
2024-12-30 10:30:00 |
Czytaj oryginał (ang.) |
| Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term |
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL. |
zacks.com |
2024-12-23 10:50:17 |
Czytaj oryginał (ang.) |
| Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition |
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). |
prnewswire.com |
2024-12-09 14:02:00 |
Czytaj oryginał (ang.) |
| Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS |
SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). |
prnewswire.com |
2024-12-02 10:05:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% |
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-19 12:56:18 |
Czytaj oryginał (ang.) |
| 5 Relative Price Strength Options Available for Investors |
RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength. |
zacks.com |
2024-11-18 18:01:16 |
Czytaj oryginał (ang.) |
| Rigel to Present at the Jefferies London Healthcare Conference |
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST). |
prnewswire.com |
2024-11-12 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript |
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-08 00:25:28 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates |
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2024-11-07 20:21:12 |
Czytaj oryginał (ang.) |
| Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update |
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarter Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. |
prnewswire.com |
2024-11-07 18:01:00 |
Czytaj oryginał (ang.) |
| Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition |
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS - Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually. |
prnewswire.com |
2024-11-05 11:05:00 |
Czytaj oryginał (ang.) |
| Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update |
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. |
prnewswire.com |
2024-10-31 10:05:00 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) |
SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO® (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). |
prnewswire.com |
2024-10-24 20:35:00 |
Czytaj oryginał (ang.) |
| Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE® |
ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE ® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction. |
globenewswire.com |
2024-10-16 14:00:00 |
Czytaj oryginał (ang.) |
| Rigel Pharmaceuticals: Looking For More Growth |
Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical negative EPS, Rigel has shown upward revenue trends, with recent earnings revealing a 37.03% year-over-year revenue increase and a reduced net loss. Growth opportunities include expanding product labels, advancing the R289 program, and leveraging partnerships, particularly in the growing hematology and oncology markets. |
seekingalpha.com |
2024-10-10 11:32:41 |
Czytaj oryginał (ang.) |
| Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships |
Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company's international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology. |
seekingalpha.com |
2024-10-10 00:42:02 |
Czytaj oryginał (ang.) |
| Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). |
prnewswire.com |
2024-10-04 12:05:00 |
Czytaj oryginał (ang.) |
| Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? |
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-25 09:35:21 |
Czytaj oryginał (ang.) |
| Rigel to Present at the 2024 Cantor Global Healthcare Conference |
SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19, at 9:10 am ET in New York, NY. |
prnewswire.com |
2024-09-12 12:05:00 |
Czytaj oryginał (ang.) |